Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Obie McNair

Internal Medicine Jackson, MS Medical Doctor

NPI 1851321384 CMS profile 38275

1134 Winter St, Jackson, MS 39204

Open in the dashboard

General payments

$4,289

46 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Obie McNair of Jackson, MS is reported in the CMS Open Payments database as having received $4,289 across 46 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,841 9
2023 General $141 9
2022 General $29 2
2021 General $128 2
2020 General $532 11
2019 General $617 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Obie McNair
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Obie McNair were reported at $2,841. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Obie McNair Internal Medicine median Middle half National median
2019 $617 $159 $48–$570 $163
2020 $532 $119 $33–$402 $114
2021 $128 $135 $37–$521 $132
2022 $29 $141 $42–$496 $149
2023 $141 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $2,841 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Moderna TX, Inc. $2,688 1 payment
  2. GlaxoSmithKline, LLC. $651 26 payments
  3. AstraZeneca Pharmaceuticals LP $244 3 payments
  4. Sanofi-Aventis U.S. LLC $183 2 payments
  5. Gilead Sciences, Inc. $110 2 payments
  6. Amarin Pharma Inc. $106 1 payment
  7. Novo Nordisk Inc $94 1 payment
  8. Global Blood Therapeutics, Inc. $90 5 payments
  9. Pfizer Inc. $58 1 payment
  10. Sunovion Pharmaceuticals Inc. $21 1 payment
  11. Other $45 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $2,688 1 payment
  2. Food and Beverage $1,602 45 payments
Products named General payments · program years 2019–2025
  1. mResvia $2,688 1 payment
  2. TRELEGY ELLIPTA $270 18 payments
  3. NUCALA Immunology $133 5 payments
  4. AREXVY $125 1 payment
  5. BREZTRI AEROSPHERE $124 1 payment
  6. NUCALA Respiratory $123 2 payments
  7. FARXIGA $120 2 payments
  8. SOLIQUA 100/33 $114 1 payment
  9. Vascepa $106 1 payment
  10. Ozempic $94 1 payment
  11. Other $463 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 130 drugs

Part D claims

7,318

Median for Internal Medicine: 777

Drug cost

$409,020

Median for Internal Medicine: $73,373

Branded share of claims

24.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 126 $95,616
Jardiance Empagliflozin Brand 106 $78,649
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 30 $20,368
Oxycontin Oxycodone Hcl Brand 15 $19,695
Entresto Sacubitril/Valsartan Brand 15 $16,406
Ozempic Semaglutide Brand 17 $16,110
Trulicity Dulaglutide Brand 11 $12,351
Myrbetriq Mirabegron Brand 14 $11,222
Symbicort Budesonide/Formoterol Fumarate Brand 30 $9,504
Brilinta Ticagrelor Brand 18 $8,891

The 10 drugs with the highest cost, of 130 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$472

Medicare's payments for the services billed

Medicare patients

36

Average age 74

Services billed

62

14 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 69%
Arthritis 44%
Chronic kidney disease 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record